Cornercap Investment Counsel Inc. Invests $67,000 in Sana Biotechnology, Inc. (NASDAQ:SANA)

Cornercap Investment Counsel Inc. purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the 3rd quarter, Holdings Channel reports. The fund purchased 16,218 shares of the company’s stock, valued at approximately $67,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ProShare Advisors LLC raised its stake in shares of Sana Biotechnology by 14.8% in the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock valued at $327,000 after acquiring an additional 4,210 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after purchasing an additional 9,940 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares during the last quarter. Finally, Algert Global LLC bought a new position in shares of Sana Biotechnology in the second quarter valued at about $73,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on SANA shares. Citigroup raised their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 9th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Sana Biotechnology in a report on Monday, November 11th.

Sana Biotechnology Trading Down 3.3 %

Sana Biotechnology stock opened at $2.34 on Tuesday. Sana Biotechnology, Inc. has a 1 year low of $2.31 and a 1 year high of $12.00. The company has a market cap of $522.45 million, a PE ratio of -1.67 and a beta of 1.44. The company’s 50-day moving average is $3.87 and its two-hundred day moving average is $5.49.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. Research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Insider Activity

In other news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the completion of the sale, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. This represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.10% of the stock is currently owned by company insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.